Appendix

Jump to

Appendix 1: Use and doses of long-term inhaled bronchodilator and corticosteroids determined in response trials

Response Drug Dose (mcg)              Frequency Delivery
  • Improved airway function
  • Improved exercise capacity
  • Reduced breathlessness
    Improved quality of life
beta-agonist
Salbutamol 100-200mcg 4-6-hourly MDI/spacer
Salbutamol 200-400mcg 4-6-hourly DPI
Terbutaline 500-1500mcg 6-8-hourly DPI
Salmeterol 50mcg 12-hourly MDI/DPI
Formoterol 12mcg 12-hourly MDI/DPI
Indacaterol 150-300mcg 24-hourly DPI

Anticholinergic (Antimuscarinic)

Ipratropium 42-84mcg 6-8-hourly MDI/spacer
Tiotropium 18mcg 24-hourly DPI
Tiotropium 2.5mcg 24-hourly Respimat
Glycopyrronium 50mcg 24-hourly DPI
Corticosteroid Inhaled
Beclometasone
(small particle)
50-200mcg/day 12-hourly MDI/spacer
Budesonide 400mcg 12-hourly DPI
Fluticasone propionate 250-500mcg/day 12-hourly MDI/DPI
Fluticasone furoate 100mcg/day 12-hourly DPI
Ciclesonide 80-320mcg/day 24-hourly MDI – spacer not recommended
MDI=metered dose inhaler. DPI=dry powder inhaler.

 

Appendix 2: Explanation of inhaler devices

Delivery system Available products Considerations
Metered dose inhaler (MDI) Ventolin, Asmol, Airomir, Epaq (salbutamol 100mcg); Atrovent (ipratropium bromide 21mcg); Qvar (beclometasone 50mcg, 100mcg); Alvesco (ciclesonide 80mcg, 160mcg); Flixotide (fluticasone 50mcg, 125mcg, 250mcg); Serevent (salmeterol 25mcg); Seretide (salmeterol 25mcg and fluticasone 50mcg, salmeterol 25mcg and fluticasone 125mcg, salmeterol 25mcg and fluticasone 250mcg); Symbicort Rapihaler (budesonide 200mcg and formoterol 6 mcg)
  • MDIs should be used with a spacer device, as some people have difficulty coordinating the release of medication with inhalation.
Spacers Aerochamber Breath-A-Tech Fisonair Nebuhaler Volumatic
  • The spacer chamber acts as a reservoir for the aerosol released from an MDI. The patient can then inhale from this chamber without having to coordinate the release of the medication.
  • Use of spacers with inhaled corticosteroids reduces side effects of oral candidiasis and hoarseness, as well as optimising medication delivery.
  • MDI with spacer is as effective as a nebuliser if an equivalent dose is taken; 10-15 puffs of 100mcg salbutamol MDI via a spacer is therapeutically equivalent to a 5mg salbutamol nebule.
  • Spacers are cheap, portable, easily cleaned and maintained, do not require electricity and are simple and quick to use.
  • A small volume spacer is preferable when the vital capacity is less than 1.5L.
Autohaler Airomir (salbutamol 100mcg); Qvar (beclometasone 50mcg, 100mcg)
  • Breath-activated MDI containing 200 doses of medication.
  • Use can improve lung deposition in patients with poor MDI inhaler technique. As the patient starts a slow, deep breath through the mouthpiece, a flap valve is triggered, and the dose automatically releases.
Dry powder inhalers
(DPI)
Accuhaler Serevent (salmeterol 50mcg); Flixotide (fluticasone 100mcg, 250mcg, 500mcg); Seretide (salmeterol 50mcg and fluticasone 100mcg, salmeterol 50mcg and fluticasone 250mcg, salmeterol 50mcg and fluticasone 500mcg)
  • Breath-activated multi-dose DPI containing 60 individually sealed doses. A dose counter shows the number of doses remaining. It gives accurate and consistent drug delivery over a range of inspiratory flow rates (30-120 L/minute).
  • Lactose powder is combined with the active medication for patients to taste and reassure them that they have inhaled a dose.
Aerolizer Foradile (formoterol 12mcg)
  • Breath-activated single-dose powder inhaler that comes with a sheet of 60 capsules in push-out foil sheet. One capsule is loaded into the inhaler and pierced before inhaling.
  • Gives consistent drug delivery over a range of inspiratory flow rates.
Turbuhaler Bricanyl (terbutaline 500mcg); Pulmicort (budesonide 100mcg, 200mcg, 400mcg); Oxis (formoterol 6mcg, 12mcg); Symbicort (formoterol 6mcg and budesonide 100mcg , formoterol 6mcg and budesonide 200mcg, formoterol 12mcg and budesonide 400mcg)
  • Breath-activated multi-dose inhaler, containing 60 (Oxis, Symbicort) or 200 (Pulmicort, Bricanyl) doses; ensures delivery without the need to coordinate inspiration with drug release.
  • Dose delivery is halved if the patient cannot produce inspiratory flow above 30 L/min. Very few patients with COPD cannot produce a rate of >60 L/min.
  • Produces very fine powder, so patients often don’t taste anything.
  • Dose indicator shows when there are 20 doses remaining, and then when the inhaler is empty (it contains a drying agent that can be heard when the inhaler is shaken, which can be misinterpreted as available medication).
HandiHaler Spiriva (tiotropium 18mcg)
  • Breath-activated dry powder inhaler. A capsule containing tiotropium is dropped into the HandiHaler, and pierced by pressing a button. The patient then inhales through the mouthpiece for effective drug delivery. Studies have shown that patients with a wide range of disease severity are able to generate sufficient inspiratory airflow (as low as 20 L/min) to evacuate the powder from the capsule.
Breezhaler Onbrez (indacaterol 150mcg, 300 mcg)

Seebri (glycopyrronium 50mcg)

Ultibro (indacaterol 110 mcg/glycopyrronium 50 mcg)

  • Breath-activated single-dose powder inhaler
  • Capsules come in foil packs containing 30 capsules in a cardboard carton
  • Breezhaler inhalation device allows oral inhalation of the content of the capsule shell. One capsule is loaded into the inhaler and pierced before inhaling.
  • Gives consistent drug delivery over a range of inspiratory flow rates.
Genuair Bretaris (aclidinium 322 mcg/dose)

Brimica (aclidinium 340 mcg/ formoterol 12 mcg)

  • Breath activated multi-dose DPI (containing 30 or 60 doses) with an integral dose indicator, a green dosage button and a coloured control window. Before inhaling the dose, the green button should be pressed all the way down and then released. The coloured control window changes to green suggesting the dose is ready for inhalation. If the full dose is inhaled correctly, the control window turns red. Genuair is equipped with a dose indicator, displaying intervals of 10 (60, 50, 40, 30, 20, 10, 0). When a red striped band appears in the dose indicator, only a few doses are left in the device. Bretaris Genuair also contains lactose.
Ellipta Breo (fluticasone furoate 100 mcg and vilanterol trifenatate 25 mcg)
  • Breath activated multi-dose DPI containing 14 or 30 doses. The active substances are in separate blisters in powder form inside the device. It has a dose counter; when fewer than 10 doses are left, half of the dose counter shows red.
 Soft mist inhaler Spiriva Respimat (tiotropium 2.5 mcg)

Spiolto Respimat (tiotropium 2.5 mcg/olodaterol 2.5 mcg)

  • Push-button activated solution for inhalation. The cartridge is inserted and primed before first use of the Respimat. To deliver the inhalation, the clear base is turned until it clicks, the cap is opened, and the patient closes their lips around the mouthpiece. The dose-release button is pressed, and the mist is inhaled with a slow, deep breath, then a breath hold. A dose indicator shows a low number of doses left, and the inhaler locks when empty.  May be suitable for patients with poor inspiratory effect.
Nebulisers Most nebulisers are electric. Some ultrasonic nebulisers are battery operated. These models are not heavy duty, but are ideal for travelling. There are also 12-volt pumps that plug into a car cigarette lighter. Use of inhaled corticosteroids requires a high-flow, heavy- duty pump.
  • Corticosteroid or ipratropium bromide aerosol should not be allowed to enter the eyes to avoid the risk of side effects such as glaucoma or urinary outlet obstruction. Patients should be advised to wipe their face dry after using the nebuliser to remove medication from the skin.
  • Ipratropium can be combined with beta-agonist, but not with corticosteroid.
The products listed are not all subsidised under the Pharmaceutical Benefits Scheme for use in COPD.

 

Appendix 3: Long term oxygen therapy (McDonald 2016)

Initiating oxygen therapy

  • Before introducing oxygen therapy, ensure optimal treat­ment of the pulmonary disorder while monitoring improve­ment with objective tests such as FEV1 and forced vital capacity (FVC). Treatment may include maximum therapy for airway obstruction, attention to nutrition and bodyweight, an exercise rehabili­tation program, control of infection, and treatment of cor pulmonale.
  • In patients selected for oxygen therapy, assess the ade­quacy of relief of hypoxaemia (PaO2 > 60 mmHg, or 8 kPa; SpO2 > 90%) and/or improvement in exercise capacity or nocturnal arterial oxygen saturation while using a practical oxygen delivery system.

What the patient needs to know

  • Patients receiving oxygen therapy in the home, and their carers, should have the use clearly explained. That is, hours of use and flow rate, and any need to vary flow rates at given times. The equipment and its care, including how to obtain servicing or replacements, needs to be explained. The dangers of open flames (especially cigarettes, gas heaters and cookers) need to be emphasised.
  • Flow should be set at the lowest rate needed to maintain a resting PaO2 of 60 mmHg (8kPa) or SpO2 > 88%. For patients with COPD, 0.5-2.0 L/min is usually sufficient. Flow rate should be increased by 1 L/min during exercise.
  • Humidifiers are generally not needed at oxygen flow rates below 4 L/min.
  • Extrasoft nasal prongs are recommended for continuous oxygen use, but may become uncomfortable at flow rates over 2-3 L/min and in the long term. Facemasks may be preferred for at least some of the time, although there are dangers of rebreathing exhaled CO2 at flow rates below 4 L/min.

Review

  • Reassess 4-8 weeks after starting continuous or noctur­nal oxygen therapy, both clinically and by measurement of PaO2 and PaCO2, with and without supplementary oxygen. A decision can then be made as to whether the treatment has been properly applied and whether it should be contin­ued or abandoned.
  • Patients on intermittent oxygen therapy should also be reassessed periodically. The review can be undertaken by appropriately trained staff using a pulse oximeter to confirm hypoxaemia (SpO2 < 88%) at rest or during daily activities. They should also check compliance with therapy and smok­ing status.
  • Review at least annually, or more often according to the clinical situation.

Dangers

  • Supplementary oxygen in patients with increased arterial PaCO2 may depress ventilation, increase physiological dead space, and further increase arterial PaCO2. This is suggested by the development of somnolence, headache and disorien­tation.
  • In long-term oxygen therapy, the increase in arterial PaCO2 is usually small and well tolerated. However, serious hypercapnia may occasionally develop, making continued oxygen therapy impractical. Risk appears greater during exacerbations of disease or if the flow of oxygen is increased inappropriately.
  • Sedatives (particularly benzodiazepines), narcotics, alco­hol and other drugs that impair the central regulation of breathing should not be used in patients with hypercapnia receiving oxygen therapy.

Choosing the right method (see Adult Domiciliary Oxygen therapy Clinical Practice Guideline for further details)

Domiciliary oxygen therapy can be delivered via the following systems:

  • Stationary oxygen concentrators: These floor-standing electrically driven devices work by extracting the nitrogen from room air by means of molecular sieves and deliver a continuous flow of oxygen at the outlet. The percentage of oxygen is around 90 to 95% depending on the model used. A back-up standard D-size oxygen cylinder is often supplied in case of concentrator breakdown or power failure. Users may claim a rebate on their electricity account.
  • Portable oxygen concentrators: These are small, lightweight portable oxygen concentrators (POC) that are powered by the household electrical supply or via a car battery or rechargeable battery which makes them suitable for ambulatory use.  Some models have been approved by some of the commercial airlines. Two types are available, those that are only capable of delivering pulsed oxygen (these are generally smaller and lighter in weight) and those that can deliver both pulsed and continuous flow oxygen. The performance specifications of the different models of POCs vary considerably and for patients with high oxygen needs, some POCs may not achieve a sufficient concentration of inspired oxygen to meet the patient’s needs during exercise.
  • Cylinders: These contain compressed oxygen gas and deliver 100% oxygen at the outlet. Portable lightweight cylinders are available. Electronic conservation devices are often supplied to deliver oxygen predominantly during inspiration and therefore avoid wastage. Demand flow devices are the most common and deliver a pre-set volume or bolus of oxygen in early inspiration. Use of such devices results in up to a fourfold reduction in oxygen consumption. Reservoir-style conservers (i.e. nasal cannulae with an integrated pendant shaped reservoir) are a cost-effective alternative.

The prescription should always specify:

  • the source of supplemental oxygen;
  • method of delivery;
  • duration of use; and
  • flow rate at rest, during exercise and during sleep.

There is no significant difference in the quality of oxygen delivery among the above methods. However:

  • Concentrators are cheaper than cylinders if use is equiva­lent to or more than three E-size cylinders per month.
  • Concentrators can be wheeled around the home but are heavy (about 21–26 kg) and are difficult to move up stairs and in and out of cars.
  • Concentrators cannot be used for nebulisation, as the pressure delivered is too low (35–63 kPa, compared with 140 kPa for nebuliser pumps).
  • If the anticipated need is for longer than three years, it is cheaper to buy than to rent a unit. The units usually have a five-year guarantee. However, public funding is available for pensioners and Health Care Card holders, subject to means testing.

 

Appendix 4 – Strategies that may assist in reminding people to reduce sedentary time

TV viewingDuring each advertisement break, stand up and go for a short walk around your house.
ReadingAt the end of each book chapter or after a few pages of the newspaper, stand up and go for a short walk around your house.
TransportStand up whilst waiting for a bus or train.
Daily tasksWhen ironing, put items away in multiple small trips rather than putting everything away once you have finished.
Computer useConsider setting an alarm (e.g. on your phone) to remind you to stand up every 30 minutes.
Phone useConsider standing up to use your phone. Go for a short walk around your house after you finish using your phone to call / text someone.

 

Appendix 5 – Table of Minimum Clinically Important Differences (MCID) (Cazzola 2015b)

Health status measures

Patient Reported Outcome Measure (PROM)PurposeDomainsNo. itemsReliabilityValidityMCID
St George’s Respiratory Questionnaire
(SGRQ)
Assess health status impairment in airways disease(COPD, Asthma, Bronchiectasis) Symptoms, activity, impacts 50 4 units
St George’s Respiratory Questionnaire COPD
(SGRQ-C)
Assess health status in COPD – weakest items removed Symptoms, activity, impacts 404 units
Chronic Respiratory Questionnaire
(CRQ)
(short form also available)
Health-related quality of life in chronic respiratory disease Mastery, fatigue, emotional function and dyspnoea 200.5 units
Clinical COPD Questionnaire
(CCQ)
Health status assessment in a primary care setting Symptoms,
functional state, mental state
100.4 units
COPD Assessment Test
(CAT)
Quantifies symptom burden of COPD, health status measurement Energy, Sleep, confidence, activities, breathlessness, chest tightness, phlegm, cough 82 units

Symptom measures

Patient Reported Outcome Measure (PROM)PurposeDomainsNo. itemsReliabilityValidityMCID
Modified Medical Research Council
(MMRC)
Disability from COPD related to breathlessness Uni-dimensional 1 - 5 point scale ~ 1, but limited data
Baseline Dyspnoea Index (BDI)
Transitional Dyspnea Index (TDI)
Measurement of dyspnea based on activities of daily living BDI: functional impairment, magnitude of task, magnitude of effort BDI 3
TDI 3
1 unit in TDI
The Breathlessness Cough and Sputum Scale (BCSS) Tracks severity of resp symptoms and evaluate efficacy in clinical trials - COPD Breathlessness, cough, sputum 3AcceptableAcceptable>1 substantial
.6 mod
.3 small
Dyspnoea 12 Current level of breathlessness severity Uni-dimensional 12Not yet established

Exacerbations

Patient Reported Outcome Measure (PROM)PurposeDomainsNo. itemsReliabilityValidityMCID
The EXAcerbations of Chronic Pulmonary Disease Tool (EXACT®)Evaluates frequency, severity and duration of an AE COPD
(Daily)
Breathlessness, cough and sputum, chest symptoms 14Not yet established
Evaluating Respiratory Symptom
(E-RS®)
Derivative instrument of the EXACT, designed to address the need for a standardized daily diary to assess respiratory symptoms in patients with stable COPD Breathlessness, cough and sputum, chest symptoms 11 3 point Δ(total score)
2 point Δ(breathless-ness)
1 point Δ(cough & sp)
1 point Δ(chest symptoms)

 

Appendix 6: Table of Systematic Reviews Evaluating the Effect of Self-Management in COPD

Appendix 6: Table of Systematic Reviews Evaluating the Effect of Self Management in COPD

AuthorsDesignStudies includedParticipant n=AimsInterventiona.b.c.d.e.f.g.h.i.j.k.
Dickens 2014RCT32 studies, database inception-20133941To examine the characteristics of complex interventions intended to reduce the use of urgent and unscheduled healthcare among people with COPDMultiple components and/or professionals, individual, group, phone or computer. Including education, rehabilitation, psychological therapy, social intervention, organisational intervention (e.g. collaborative care or case management), psychological drug trials. Simple interventions, e.g. new treatment for underlying long-term condition, compared to treatment as usual excluded+
Majothi 2015RCT9 studies, Moderate-severe COPD, database inception-20121466To evaluate the effect of COPD self-management following admission to hospital1+ components commonly included in self-management interventions, e.g. action plans, exercise, education, inhaler technique, bronchial hygiene and breathing techniques, stress management and relaxation, nutritional programs, patient empowerment, support groups and telecare, provided in hospital or community setting with a usual care, control, sham intervention or other self-management intervention comparator.+///
Cannon 2016RCT25 studies, 1990-20164082To analyse the outcome of self-management RCTs and their impact upon COPD patients' health outcomes using meta-analysisSelf-management intervention including at least 4 of the following: Exacerbation action plan, COPD education, medication information, management of exacerbations, management of stress and/or anxiety, nutritional guidance, exercise program/information, or managing a healthy lifestyle.+//+
Howcroft 2016RCT, quasi RCT7 studies, Database inception -20151550Compare COPD exacerbation action plans with a single short educational component + ongoing support directed at use of action planAction plan with a single educational component of short duration allowing time for the clinician to personalise plan. Ongoing support delivered by phone or direct contact. Studies with broader self-management support interventions, e.g. education in multiple sessions over a longer period or exercise programmes, with or w/out an action plan were excluded. Active intervention was compared to ’usual care’.+/+/+
Jolly 2016RCT173 studies, database inception-2012n/aTo identify the most effective components of interventions to facilitate self-management of health care behavioursInclude 3+ components e.g. structured group-based PR programs (to teach self-management skills); educational self-management interventions delivered in an outpatient setting or at home, sometimes with telephone follow-up; integrated disease management with multidisciplinary input and often some element of monitoring by health professionals; exercise-only interventions (with some dyspnoea management) and respiratory muscle training using threshold devices.+/
Jonkman 2016RCT14 studies, 1985-20133282Determine if self-management programs were associated with better outcomes and if any subgroups benefit moreInterventions providing information to patients and including 2+ of: stimulation of sign/symptom monitoring; education in problem solving skills, i.e. self-treatment of acute exacerbations and stress/symptom management; smoking cessation; and stimulation of medical treatment adherence; physical activity; or improving dietary intake. Components aimed at enhancing the patient’s active role and responsibility.+++/
Lenferink 2017RCT22 studies, 1995-20173854To evaluate the efficacy of COPD-specific self-management interventions that include an action plan for exacerbationsMust include a written action plan for AECOPD and an iterative process between participant and healthcare provider(s) in which feedback was provided.+/+///-
Newham 2017RCT26 RCTs identified from 11 systematic reviews3,518
(1,827 intervention, 1,691 control)
To summarize the current evidence base surrounding the effectiveness of self-management interventions for improving HRQOL in people with COPD.Intervention descriptions were coded for behaviour change techniques (BCTs) that targeted self-management behaviours to address 1) symptoms, 2) physical activity, and 3) mental health. Comparator was usual care.++
Long 2017RCT10 studies, database inception-August 20181,959To systematically review the evidence for health coaching as an intervention to improve health-related quality of life (HRQoL) and reduce hospital admissions in people with chronic obstructive pulmonary disease (COPD)Intervention must include evidence of goal setting, motivational interviewing techniques, and COPD-related health education. Interventions that do not have clear evidence of all three components will be excluded. The intervention must be delivered by a qualified HCP, over a minimum of two sessions, either face to face, by telephone, online, email, tablet, smartphone, or a combination of these methods. Interventions that include group, instead of individual, coaching sessions will be excluded. Trials must consist of one group that received the health coaching intervention and one group that received either treatment as usual, wait-list control, or a no intervention control group,+/+/
Jolly 2018RCT12 studies, database inception-201210,647To evaluate whether self-management intervention sin COPD patients recruited from primary care lead to improved health-related quality of life, improved health outcomes and reduced health care utilisation.Interventions were heterogeneous by duration (one month to at least 2 years); provider (GPs, nurse practitioners, medical assistants, respiratory physician nurses, health psychologists and trained peers, or a combination); and focus (exacerbation management and responding to participants self-management queries or very comprehensive programmes including information about educational materials, physical activity advice, smoking cessation, breathing and medication management).
The control arm of studies was most frequently usual care, with two studies providing information booklets as part of the control arm and one using usual care with an assessment of the patients’ health status every 2 months.
//
Aranburu-Imatz 2022Systematic review and meta-analysis of observational studies (case–control, cohort and cross-sectional) or intervention study (randomised or non-randomised)48 studies met the inclusion criteria for qualitative analysis, of which 25 were considered for meta-analysis, 2009-20215,215 patients in 48 studiesTo analyse the effect of hospital or community nurse-led interventions in the follow-up and management of COPD patients in terms of mental, physical, and clinical statusNurse-led intervention. Heterogeneity was observed as regards the type of interventions and scope of care.++++
Schrijver 2022RCTs and cluster RCTs27 studies, 1995-20226,008To evaluate the effectiveness of COPD self‐management interventions compared to usual care in terms of health‐related quality of life (HRQoL), respiratory‐related hospital admissions, respiratory‐related mortality and all‐cause mortality.Self-management interventions compared to usual care.++//
+ = improved; /= no change; - = worsened; blank = not measured.
6MWD= 6-minute walk distance, CCT= controlled clinical trials, COPD= chronic obstructive pulmonary disease, ED= emergency department, HRQoL= health-related quality of life, RCT= randomised controlled trial, PR = pulmonary rehabilitation.
a. Health-related quality of life (HRQoL); b. All-cause hospitalisations; c. Respiratory-related hospitalisations; d. Mortality; e. emergency department presentations; f. Anxiety & depression; g. Dyspnoea; h. 6-minute walking distance (6MWD); i. Respiratory-related mortality; j. Medication use; k. Urgent healthcare utilisation